Nasdaq:US$14.48 (+0.07) | HKEX:HK$23.70 (+0.60) | AIM:£2.29 (+0.02)
新聞中心及演示文稿
上一篇文章   |   下一篇文章
公告主題, 監管通知 | 2023-02-28

Publication of Form 20-F

Hong Kong, Shanghai & Florham Park, NJ: Tuesday, February 28, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today published the Form 20-F for the financial year ended December 31, 2022.  This is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/3620R_1-2023-2-28.pdf  and also on the website of the Company at www.hutch-med.com.

 

About HUTCHMED

HUTCHMED (Nasdaq/AІM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. Іt is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Іt has more than 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.